Genedx Holdings CORP Form 4 insider transactions

GeneDx Holdings Corp. CFO Kevin Feeley sold a total of 1,430 shares of Class A Common Stock on January 2, 2025, under a pre-arranged 10b5-1 trading plan.

GeneDx Holdings Corp. CEO Katherine Stueland sold 10,501 shares of Class A Common Stock to cover tax obligations following the vesting of restricted stock units.

GeneDx Holdings CFO Kevin Feeley sold 3,728 shares of Class A Common Stock at $76.7541 per share to cover tax obligations following the vesting of restricted stock units.

GeneDx Holdings CEO, Katherine Stueland, sold 3,661 shares of Class A Common Stock to cover tax obligations following the vesting of restricted stock units.

GeneDx Holdings CFO, Kevin Feeley, sold shares to cover tax obligations related to the vesting of restricted stock units.

GeneDx Holdings CFO Kevin Feeley acquired shares through restricted stock unit vesting and sold shares to cover tax obligations.

GeneDx's Chief Financial Officer, Kevin Feeley, sold a total of 27,040 shares of Class A Common Stock over two days, November 21st and 22nd, under a pre-arranged 10b5-1 trading plan.

A GeneDx Holdings director, Joshua Ruch, amended a previous filing to include indirect holdings of Class A Common Stock through various investment entities.

GeneDx Holdings director Jason Ryan transferred 141,356 shares to a Grantor Retained Annuity Trust (GRAT) and sold a total of 46,296 shares in multiple transactions.

Icahn School of Medicine at Mount Sinai sold a significant number of GeneDx Holdings Corp. shares in two transactions on November 15th and 18th, 2024.

GeneDx Holdings CEO, Katherine Stueland, sold a total of 48,387 shares of Class A Common Stock across multiple transactions on November 15th and 18th, 2024, under a pre-arranged 10b5-1 trading plan.

Icahn School of Medicine at Mount Sinai, a 10% owner of GeneDx Holdings Corp., disposed of 865,800 shares of Class A Common Stock on October 31, 2024, at a price of $75 per share.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock related to restricted stock units.

Katherine Stueland, CEO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock related to restricted stock units.

Director Jason Ryan reports the acquisition of 130 shares of Class A Common Stock through the vesting of restricted stock units.

Director Joshua Ruch reports the vesting of restricted stock units into Class A Common Stock of GeneDx Holdings Corp.

Katherine Stueland, CEO of GeneDx Holdings Corp., reports acquisition and disposal of Class A Common Stock related to RSU vesting and tax obligations.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units to cover tax obligations.

Kevin Feeley, CFO of GeneDx Holdings Corp., sold 895 shares of Class A Common Stock on September 9, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Katherine Stueland, CEO of GeneDx Holdings Corp., sold shares to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock related to restricted stock units.

Opko Health, a significant shareholder in GeneDx Holdings Corp., has sold a portion of its Class A Common Stock in a series of transactions.

Opko Health, a significant shareholder of GeneDx Holdings Corp., has sold a portion of its Class A Common Stock in two transactions.

Opko Health, a significant shareholder of GeneDx Holdings Corp., has sold a portion of its Class A Common Stock in two transactions.

Casdin Capital and related entities report transactions involving Class A Common Stock of GeneDx Holdings Corp.

OPKO HEALTH, INC. reports the sale of 88,839 shares of GeneDx Holdings Corp. Class A Common Stock at an average price of $33.5027.

Opko Health, a significant shareholder in GeneDx Holdings Corp., recently sold 50,000 shares of Class A Common Stock at an average price of $33.8578.

Katherine Stueland, CEO of GeneDx Holdings Corp., reports the acquisition and disposition of Class A Common Stock related to restricted stock units.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the vesting and sale of Class A Common Stock to cover tax obligations.

Opko Health, a significant shareholder of GeneDx Holdings Corp., has sold a portion of its Class A common stock in two transactions.